Evidence map›Paper›PMID 18363100›Full record

ReviewNeurochemical research2009

Oxidative and inflammatory pathways in Parkinson's disease.

Rebecca L Miller, Marilyn James-Kracke, Grace Y Sun, Albert Y Sun

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurochemical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 3 syntheses or guidelines pooled it, 305 citations in OpenAlex.

  1. The relationship between obstructive sleep apnea and Parkinson's disease: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Pooled it
  2. Pooled it
  3. Dietary fat intake, pesticide use, and Parkinson's disease.Parkinsonism & related disorders · 2014
    Pooled it
  4. Coenzyme Q10 deficiency in patients with Parkinson's disease.Journal of the neurological sciences · 2012
    Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rebecca L MillerDepartment of Medical Pharmacology and Physiology, University of Missouri - Columbia, Columbia, MO, 65212, USA.
Marilyn James-Kracke
Grace Y Sun
Albert Y Sun
University of Missouri · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most prevalent age-related neurodegenerative disease with physiological manifestations including tremors, bradykinesia, abnormal postural reflexes, rigidity and akinesia and pathological landmarks showing losses of dopaminergic neurons in the substantia nigra. Although the etiology of PD has been intensively pursued for several decades, biochemical mechanisms and genetic and epigenetic factors leading to initiation and progression of the disease remain elusive. Environmental toxins including (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) MPTP, paraquat and rotenone have been shown to increase the risk of PD in humans. Oxidative stress remains the leading theory for explaining progression of PD. Studies with cell and animal models reveal oxidative and inflammatory properties of these toxins and their ability to activate glial cells which subsequently destroy neighboring dopaminergic neurons. This review describes pathological effects of neurotoxins on cells and signaling pathways for production of reactive oxygen species (ROS) that underline the pathophysiology of PD.

Indexed as

Oxidative Stress1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsHerbicidesHumansInflammationLipopolysaccharidesMicrogliaMitogen-Activated Protein KinasesNADPH OxidasesNeurotoxinsNitric Oxide SynthaseOxidopamineParaquatParkinson DiseaseParkinsonian Disorders1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineHerbicidesLipopolysaccharidesMitogen-Activated Protein KinasesNADPH OxidasesNeurotoxinsNitric Oxide SynthaseOxidopamineParaquatProtein Kinase CRotenone

Identifiers

PMID18363100
OpenAlexW2066762007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.